Clinical trials: Cardiovascular Disease Prevention
Arthroplasty, Replacement, Knee, Thromboembolism
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
To determine the comparative efficacy and safety of two different doses (75mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran administered orally (capsules), compared…
- Trial name
- NCT00152971
- Testing
- Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion
- Where
- 94 sites in United States, Canada and 2 more
- Volunteers
- 2,615 people
- Sponsor
- Boehringer Ingelheim
Prevention of Stroke or Systemic Embolism, Deep Vein Thrombosis (DVT)
To Compare and Evaluate the Oral Bioavailability of Edoxaban 60 mg Film Coated Tablet With That of Lixiana® 60 mg Filmtabletten (Film Coated Tablet) (Edoxaban) in Healthy, Adult, Human Subjects Under Fasting Conditions
To compare and evaluate the oral bioavailability of Edoxaban 60 mg Film Coated Tablet with that of Lixiana® 60 mg filmtabletten (Film Coated Tablet (Edoxaban) in healthy, adult, human subjects under fasting conditions.
- Conditions
- Prevention of Stroke or Systemic Embolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- NCT06930937
- Testing
- Lixiana® Film Coated Tablet, Edoxaban Film Coated Tablet
- Where
- India
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Pulmonary Embolism, Deep Vein Thrombosis
The Angel® Catheter Pivotal Clinical Trial
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
- Trial name
- NCT02186223
- Testing
- The Angel® Catheter
- Where
- 21 sites in United States
- Volunteers
- 172 people
- Sponsor
- BiO2 Medical
Hereditary Angioedema (HAE)
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.
- Trial name
- NCT02741596
- Testing
- DX-2930
- Where
- 43 sites in United States, Canada and 5 more
- Volunteers
- 212 people
- Sponsor
- Shire
Venous Thromboembolism
ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
The primary objectives of this study is to estimate the real-world safety profile of Eliquis in Japanese Venous Thromboembolism patients and to estimate the risk factors likely to affect the incidence of bleeding.
- Trial name
- NCT02836457
- Where
- Japan
- Volunteers
- 1,134 people
- Sponsor
- Bristol-Myers Squibb
Diabetic Foot Ulcer
Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer
The purpose of this study is to determine the safety and efficacy of the topical gentamicin collagen sponge (gentamicin sponge) combined with standard of care (daily wound care, off-loading, diabetic control and debridement by a…
- Trial name
- NCT00658957
- Testing
- gentamicin-collagen sponge
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Innocoll
Hereditary Angioedema
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
- Trial name
- NCT05392114
- Testing
- Donidalorsen
- Where
- 50 sites in United States, Belgium and 12 more
- Volunteers
- 154 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
Study BT200-01 is a first in human (FIH) study in male and female normal human volunteers (NHVs) that uses an Integrated Protocol Design.
- Conditions
- Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis), Intracranial Arteriosclerosis
- Trial name
- NCT04103034
- Testing
- BT200, Desmopressin
- Where
- Austria
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Band Therapeutics
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
- Trial name
- NCT00913120
- Testing
- YM150, Enoxaparin
- Where
- 16 sites in Japan, South Korea and 2 more
- Volunteers
- 610 people
- Sponsor
- Astellas Pharma Inc
Atrial Fibrillation
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia
This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
- Trial name
- XANAP (NCT01750788)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 11 sites in Hong Kong, India and 9 more
- Volunteers
- 2,297 people
- Sponsor
- Bayer
Thromboembolism, Knee Replacement
ARIXTRA Local Study For Registration In China.
This is a local registration study in China to compare the safety and efficacy of ARIXTRA to Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of components.
- Conditions
- Thromboembolism, Knee Replacement, Hip Replacement
- Trial name
- NCT00328939
- Testing
- ARIXTRA infusion, Enoxaparine infusion
- Where
- 7 sites in China
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Myocardial Ischemia, Coronary Disease
Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury
The purpose of the study is to evaluate whether FX06 is capable of limiting infarct size following balloon catheterization for acute myocardial infarction.
- Conditions
- Myocardial Ischemia, Coronary Disease, Myocardial Infarction
- Trial name
- NCT00326976
- Testing
- FX06, Percutaneous coronary intervention
- Where
- 32 sites in Austria, Belgium and 9 more
- Volunteers
- 234 people
- Sponsor
- Fibrex Medical Research & Development GmbH
Thromboembolism
SALTO - Epidemiological Study on Compliance and Treatment Satisfaction
Patients that are on total knee/hip replacement initiate prophylaxis treatment on the hospital ground. Once they leave the hospital, as outpatients they continue with the treatment at least during two consecutive weeks.
- Trial name
- SALTO (NCT00911001)
- Testing
- No Drug
- Where
- Spain
- Volunteers
- 480 people
- Sponsor
- Bayer
Raynaud's Phenomenon
Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
Raynaud's phenomenon (RP) is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. During an attack of RP which commonly affects the hands and feet these arteries contract briefly which limits…
- Trial name
- REINO (NCT01315899)
- Testing
- ORM-12471 30mg, ORM-12471
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Orion Corporation, Orion Pharma
Peripheral Arterial Disease (PAD), Moderate Risk for Cardiovascular Disease (CVD)
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention
Non interventional study aimed to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index (ABI) not above 0.90 in subjects with a moderate risk of cardiovascular disease…
- Trial name
- PANDORA (NCT00689377)
- Where
- 331 sites in Belgium, France and 4 more
- Volunteers
- 9,000 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto…
- Trial name
- BOX-AF (NCT01855139)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Belgium
- Volunteers
- 106 people
- Sponsor
- Bayer
Cancer, Heart Failure
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Purpose：1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To…
- Conditions
- Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy
- Trial name
- NCT06092606
- Testing
- Trial group: DH001 low-dose group, Trial group: DH001 high-dose group
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Monyan Pharmaceutical (Shanghai) Co., Ltd.
Hereditary Angioedema, HAE
A Long Term Safety Study of BCX7353 in Hereditary Angioedema
This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).
- Conditions
- Hereditary Angioedema, HAE, Prophylaxis
- Trial name
- APeX-S (NCT03472040)
- Testing
- BCX7353
- Where
- 87 sites in United States, Australia and 18 more
- Volunteers
- 387 people
- Sponsor
- BioCryst Pharmaceuticals
Hereditary Angioedema (HAE)
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
The purpose of this study is to determine if an investigational treatment is safe and well tolerated when administered by intravenous (IV) infusion in Japanese subjects with HAE.
- Trial name
- NCT02865720
- Testing
- CINRYZE 500 U, CINRYZE 1000 U
- Where
- 10 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Shire
Atrial Fibrillation
A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation
The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.
- Trial name
- OPAL-2 (NCT00938730)
- Testing
- YM150, Warfarin
- Where
- 170 sites in Australia, Austria and 21 more
- Volunteers
- 1,280 people
- Sponsor
- Astellas Pharma Inc